Amarin (NASDAQ:AMRN) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, December 21st.
A number of other brokerages have also recently commented on AMRN. ValuEngine cut shares of Amarin from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the stock a “buy” rating in a research note on Wednesday, December 13th. Zacks Investment Research cut shares of Amarin from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Amarin in a research note on Thursday, November 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Amarin has a consensus rating of “Buy” and a consensus target price of $7.75.
Amarin (NASDAQ:AMRN) opened at $4.25 on Thursday. The firm has a market cap of $1,164.78, a price-to-earnings ratio of -15.74 and a beta of 0.62. Amarin has a 52 week low of $2.81 and a 52 week high of $4.47. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63.
Amarin (NASDAQ:AMRN) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million for the quarter, compared to analysts’ expectations of $45.85 million. During the same period in the previous year, the business posted ($0.08) earnings per share. The business’s revenue was up 45.4% on a year-over-year basis. equities analysts predict that Amarin will post -0.22 EPS for the current fiscal year.
In other Amarin news, insider John F. Thero purchased 10,000 shares of Amarin stock in a transaction dated Thursday, November 30th. The stock was acquired at an average price of $3.24 per share, for a total transaction of $32,400.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Steven B. Ketchum sold 64,683 shares of the business’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $4.40, for a total transaction of $284,605.20. The disclosure for this sale can be found here. Company insiders own 3.72% of the company’s stock.
Several large investors have recently bought and sold shares of AMRN. Alkeon Capital Management LLC bought a new stake in shares of Amarin in the 3rd quarter valued at about $7,875,000. University of Notre Dame DU Lac bought a new position in shares of Amarin during the 3rd quarter worth approximately $2,814,000. JPMorgan Chase & Co. raised its stake in shares of Amarin by 681.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company’s stock worth $1,121,000 after acquiring an additional 242,544 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Amarin by 135.4% during the 2nd quarter. GSA Capital Partners LLP now owns 342,800 shares of the biopharmaceutical company’s stock worth $1,381,000 after acquiring an additional 197,200 shares in the last quarter. Finally, Intrinsic Edge Capital Management LLC bought a new position in shares of Amarin during the 2nd quarter worth approximately $725,000. Institutional investors and hedge funds own 40.12% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Amarin (AMRN) Upgraded to Hold at BidaskClub” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/01/14/amarin-amrn-upgraded-to-hold-by-bidaskclub-3-updated-updated.html.
Amarin Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.